Sutro Biopharma (STRO) Expected to Announce Earnings on Monday

Sutro Biopharma (NASDAQ:STRO - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Sutro Biopharma to post earnings of ($0.63) per share and revenue of $11.61 million for the quarter.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.28). Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The firm had revenue of $17.40 million for the quarter, compared to the consensus estimate of $11.61 million. On average, analysts expect Sutro Biopharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sutro Biopharma Stock Performance

Sutro Biopharma stock traded down $0.09 during trading hours on Friday, reaching $0.87. 1,050,324 shares of the company's stock traded hands, compared to its average volume of 1,093,989. Sutro Biopharma has a fifty-two week low of $0.52 and a fifty-two week high of $5.17. The firm has a market capitalization of $73.46 million, a price-to-earnings ratio of -0.54 and a beta of 1.77. The firm's 50 day moving average is $0.85 and its 200-day moving average is $1.85.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on STRO. Citizens Jmp cut Sutro Biopharma from an "outperform" rating to a "market perform" rating in a research note on Friday, March 14th. HC Wainwright reaffirmed a "neutral" rating and set a $2.00 price target on shares of Sutro Biopharma in a research report on Tuesday, April 29th. Piper Sandler set a $2.00 price objective on Sutro Biopharma in a research report on Friday, March 14th. Bank of America downgraded shares of Sutro Biopharma from a "buy" rating to an "underperform" rating and dropped their target price for the stock from $11.00 to $1.00 in a report on Friday, March 14th. Finally, Wedbush cut shares of Sutro Biopharma from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $8.00 to $2.00 in a report on Friday, March 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, Sutro Biopharma has an average rating of "Hold" and an average price target of $6.63.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.